A Study of Treprostinil Palmitil Inhalation Powder (TPIP) In Pulmonary Arterial Hypertension (PAH)
An Open-Label Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
New York
-
New York, New York, United States, 10021-9800
- USA002
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Participant must be ≥ 18 years of age at the time of signing the informed consent
Participants must have a diagnosis of World Health Organization Group 1 Pulmonary Hypertension (PH) (PAH) with the following characteristics
- Etiology of idiopathic, heritable, drug/toxin-induced or connective tissue disease (CTD)-related PAH
- Right heart catheterization with the following hemodynamic findings:
- Mean pulmonary arterial pressure (mPAP) > 20 mmHg at rest,
- Pulmonary capillary wedge pressure (PCWP) ≤ 15 mmHg, and
- Pulmonary vascular resistance (PVR) of ≥ 3 Wood Units (WU)
- No change in pulmonary hypertension medications (eg, ambrisentan, bosentan, macitentan, sildenafil, tadalafil, riociguat) or dosage for at least 90 days prior to Screening
- No change in diuretic use or dosage for at least 30 days prior to Screening
- Body mass index (BMI) within the range 18.0 - 32.0 kg/m^2 (inclusive)
- Male participants: Male participants and their female partners of childbearing potential must agree to use highly effective contraception from Study Day 1 to at least 90 days after dosing
- Female participants: Women of child-bearing potential (WOCPB, defined as premenopausal, not surgically sterile for at least 3 months prior to Screening) must use a highly effective contraception method and agree to be tested for pregnancy from at Screening, Baseline, and 30 days after dosing
- Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in the protocol.
Exclusion Criteria:
- Any PH other than idiopathic, hereditary, drug/toxin-induced, or connective tissue disease (CTD) associated PAH (eg, congenital heart disease-associated PAH, portal hypertension-associated PAH, PH belonging to Groups 2 through 5)
- Allergy, or documented hypersensitivity or contraindication, to the ingredients of treprostinil palmitil inhalation powder (TPIP) or treprostinil (TRE)
- Previous intolerance to prostacyclin analogs or receptor agonists (eg, selexipag) per investigator discretion
- History of anaphylaxis or previously documented hypersensitivity reaction to any drug per Investigator discretion
- History of heart disease including left ventricular ejection fraction (LVEF) ≤ 40% or clinically significant valvular, constrictive, or atherosclerotic heart disease (myocardial infarction, etc)
Active liver disease or hepatic dysfunction manifested as:
- Elevated liver function test results (ALT or AST > 2 × ULN) at Screening
- Bilirubin > 1.5 × ULN (isolated bilirubin > 1.5 × ULN; ULN is acceptable if bilirubin is fractionated and direct bilirubin < 35%) at Screening.
- Known hepatic or biliary abnormalities, not including Gilbert's syndrome or asymptomatic gallstones at Screening.
- History of HIV infection/positive HIV serology test result at Screening
- History of active/chronic Hepatitis B or C/ positive hepatitis B or C serology test result at Screening
- History of abnormal bleeding or bruising
- Known or suspected immunodeficiency disorder, including history of invasive opportunistic infections (eg, tuberculosis, histoplasmosis, listeriosis, coccidioidomycosis, pneumocystosis, aspergillosis) despite infection resolution, or otherwise recurrent infections of abnormal frequency, or prolonged infections suggesting an immune-compromised status, as judged by the investigator
- Active and current symptomatic infection by SARS CoV 2
- Participants with current or recent (past 4 weeks) lower respiratory tract infection
- History of malignancy in the past 5 years, with exception of completely treated in situ carcinoma of the cervix and completely treated non-metastatic squamous or basal cell carcinoma of the skin
- Participants receiving triple combination therapy for PAH consisting of endothelin receptor agonists, phosphoesterase type 5 inhibitors, and guanylate cyclase stimulators (riociguat)
- Participants receiving prostanoids/prostacyclin agonists
- Participants receiving potent CYP2C8 inhibitors, such as gemfibrozil
- Have participated in any other interventional clinical studies within 30 days of Baseline
- Current or history of substance and/or alcohol abuse
- Current user of cigarettes or e-cigarettes
- Pregnant or breastfeeding
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Treprostinil Palmitil Inhalation Powder
Participant received a single dose of TPIP 112.5 micrograms (μg) via oral inhalation on Day 1.
The participant then entered into a 16-week Extended Use Treatment (EUT) Period during which TPIP, administered via oral inhalation, was titrated up to a mean daily dose of 320 μg.
|
Administered by oral inhalation using a Plastiape capsule-based dry powder inhaler
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Number of Participants Who Experience a Treatment Emergent Adverse Event (TEAE)
Time Frame: Up to 150 days
|
Up to 150 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change From Baseline in Pulmonary Vascular Resistance (PVR) After TPIP Administration
Time Frame: Day 1: Pre-treatment (Baseline), 8 and 24 hours post-treatment
|
Day 1: Pre-treatment (Baseline), 8 and 24 hours post-treatment
|
|
Maximum Observed Concentration (Cmax) of Treprostinil (TRE) in Plasma
Time Frame: Pre-dose and multiple timepoints post-dose up to Day 2
|
Pre-dose and multiple timepoints post-dose up to Day 2
|
|
Time to Maximum Concentration (Tmax) of Treprostinil (TRE) in Plasma
Time Frame: Pre-dose and multiple timepoints post-dose up to Day 2
|
Pre-dose and multiple timepoints post-dose up to Day 2
|
|
Area Under the Concentration-time Curve From Time 0 to Time of the Last Measurable Concentration (AUClast) of Treprostinil (TRE) in Plasma
Time Frame: Pre-dose and multiple timepoints post-dose up to Day 2
|
Pre-dose and multiple timepoints post-dose up to Day 2
|
|
Area Under the Concentration-time Curve From Time 0 to Infinity (AUC0-∞) of Treprostinil (TRE) in Pasma
Time Frame: Pre-dose and multiple timepoints post-dose up to Day 2
|
Pre-dose and multiple timepoints post-dose up to Day 2
|
|
Elimination Half-life (t1/2) of Treprostinil (TRE) in Plasma
Time Frame: Pre-dose and multiple timepoints post-dose up to Day 2
|
Pre-dose and multiple timepoints post-dose up to Day 2
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- INS1009-201
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.